Skip to main
CGTX
CGTX logo

Cognition Therapeutics (CGTX) Stock Forecast & Price Target

Cognition Therapeutics (CGTX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cognition Therapeutics Inc. has recently benefitted from a significant financial contribution from an anonymous benefactor, facilitating an expanded access program for its lead program, zervimesine, which may enhance the company’s visibility and investor confidence. Furthermore, the Phase 2 START study for zervimesine has surpassed 50% enrollment, indicating positive progress in its clinical development and potential for future commercialization. Financially, Cognition reported operational runway until 2Q26, with relatively stable R&D expenditures and a reduction in G&A expenses, demonstrating efficient financial management amid their ongoing projects.

Bears say

Cognition Therapeutics Inc. is facing significant risks from intense market competition, which may adversely affect its ability to penetrate the market and set pricing for its therapeutics targeting age-related degenerative diseases. Additionally, the company is at risk of losing patent protection for its technology and product candidate CT1812, which could limit its competitive advantage and market positioning on both national and international scales. These fundamental challenges contribute to a negative outlook for the company's stock performance.

Cognition Therapeutics (CGTX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cognition Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cognition Therapeutics (CGTX) Forecast

Analysts have given Cognition Therapeutics (CGTX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cognition Therapeutics (CGTX) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cognition Therapeutics (CGTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.